CN110214015A - 用于治疗血栓栓塞的方法 - Google Patents
用于治疗血栓栓塞的方法 Download PDFInfo
- Publication number
- CN110214015A CN110214015A CN201880007480.0A CN201880007480A CN110214015A CN 110214015 A CN110214015 A CN 110214015A CN 201880007480 A CN201880007480 A CN 201880007480A CN 110214015 A CN110214015 A CN 110214015A
- Authority
- CN
- China
- Prior art keywords
- thrombolytics
- thromboembolism
- treating
- accumulated dose
- ultrasonic wave
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000005189 Embolism Diseases 0.000 title claims abstract description 55
- 208000001435 Thromboembolism Diseases 0.000 title claims abstract description 55
- 238000000034 method Methods 0.000 title claims abstract description 52
- 230000002537 thrombolytic effect Effects 0.000 claims abstract description 190
- 229960000103 thrombolytic agent Drugs 0.000 claims abstract description 167
- 238000011282 treatment Methods 0.000 claims description 64
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 claims description 49
- 208000007536 Thrombosis Diseases 0.000 claims description 43
- 238000001802 infusion Methods 0.000 claims description 36
- 208000010378 Pulmonary Embolism Diseases 0.000 claims description 34
- 238000002604 ultrasonography Methods 0.000 claims description 33
- 230000005855 radiation Effects 0.000 claims description 32
- 239000012530 fluid Substances 0.000 claims description 22
- 229940079593 drug Drugs 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 21
- 239000003795 chemical substances by application Substances 0.000 claims description 20
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 16
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims description 16
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 16
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 16
- 230000006798 recombination Effects 0.000 claims description 13
- 238000005215 recombination Methods 0.000 claims description 13
- 229960005356 urokinase Drugs 0.000 claims description 13
- 229960000187 tissue plasminogen activator Drugs 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 239000012190 activator Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 102000001938 Plasminogen Activators Human genes 0.000 claims description 2
- 108010001014 Plasminogen Activators Proteins 0.000 claims description 2
- 230000000149 penetrating effect Effects 0.000 claims description 2
- 229940012957 plasmin Drugs 0.000 claims description 2
- 229940127126 plasminogen activator Drugs 0.000 claims description 2
- 210000005241 right ventricle Anatomy 0.000 description 29
- 208000032843 Hemorrhage Diseases 0.000 description 20
- 230000004087 circulation Effects 0.000 description 18
- 238000009826 distribution Methods 0.000 description 18
- 210000005240 left ventricle Anatomy 0.000 description 18
- 208000034158 bleeding Diseases 0.000 description 12
- 230000000740 bleeding effect Effects 0.000 description 12
- 210000001367 artery Anatomy 0.000 description 11
- 238000011284 combination treatment Methods 0.000 description 11
- 230000002146 bilateral effect Effects 0.000 description 10
- 238000011160 research Methods 0.000 description 10
- 238000002560 therapeutic procedure Methods 0.000 description 10
- 238000010968 computed tomography angiography Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 239000003146 anticoagulant agent Substances 0.000 description 8
- 229940127219 anticoagulant drug Drugs 0.000 description 8
- 230000004064 dysfunction Effects 0.000 description 7
- 239000003527 fibrinolytic agent Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 108010088842 Fibrinolysin Proteins 0.000 description 6
- 230000002708 enhancing effect Effects 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 102000013566 Plasminogen Human genes 0.000 description 5
- 108010051456 Plasminogen Proteins 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 238000012377 drug delivery Methods 0.000 description 5
- 229940001501 fibrinolysin Drugs 0.000 description 5
- 230000002792 vascular Effects 0.000 description 5
- 229960003318 alteplase Drugs 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 239000000919 ceramic Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000001147 pulmonary artery Anatomy 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000004020 conductor Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 102000010911 Enzyme Precursors Human genes 0.000 description 2
- 108010062466 Enzyme Precursors Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 102000012479 Serine Proteases Human genes 0.000 description 2
- 108010022999 Serine Proteases Proteins 0.000 description 2
- 108010039185 Tenecteplase Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000002826 coolant Substances 0.000 description 2
- 230000003073 embolic effect Effects 0.000 description 2
- 210000001174 endocardium Anatomy 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 229960002917 reteplase Drugs 0.000 description 2
- 108010051412 reteplase Proteins 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 229960000216 tenecteplase Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 208000004043 venous thromboembolism Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010014522 Embolism venous Diseases 0.000 description 1
- 208000009087 False Aneurysm Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- 206010048975 Vascular pseudoaneurysm Diseases 0.000 description 1
- 229940099983 activase Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000001627 cerebral artery Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 102000005525 fibrillarin Human genes 0.000 description 1
- 108020002231 fibrillarin Proteins 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000001435 haemodynamic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- QNZFKUWECYSYPS-UHFFFAOYSA-N lead zirconium Chemical compound [Zr].[Pb] QNZFKUWECYSYPS-UHFFFAOYSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000033885 plasminogen activation Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000003492 pulmonary vein Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000009121 systemic therapy Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000000591 tricuspid valve Anatomy 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000002396 uvula Anatomy 0.000 description 1
- 208000021331 vascular occlusion disease Diseases 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 230000010148 water-pollination Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/22—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
- A61B17/22004—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for using mechanical vibrations, e.g. ultrasonic shock waves
- A61B17/22012—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for using mechanical vibrations, e.g. ultrasonic shock waves in direct contact with, or very close to, the obstruction or concrement
- A61B17/2202—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for using mechanical vibrations, e.g. ultrasonic shock waves in direct contact with, or very close to, the obstruction or concrement the ultrasound transducer being inside patient's body at the distal end of the catheter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0092—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin using ultrasonic, sonic or infrasonic vibrations, e.g. phonophoresis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/22—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
- A61B2017/22082—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for after introduction of a substance
- A61B2017/22084—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for after introduction of a substance stone- or thrombus-dissolving
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/22—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for
- A61B2017/22082—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for after introduction of a substance
- A61B2017/22088—Implements for squeezing-off ulcers or the like on the inside of inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; Calculus removers; Calculus smashing apparatus; Apparatus for removing obstructions in blood vessels, not otherwise provided for after introduction of a substance ultrasound absorbing, drug activated by ultrasound
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Surgery (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Anesthesiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Mechanical Engineering (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Surgical Instruments (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762449966P | 2017-01-24 | 2017-01-24 | |
| US62/449,966 | 2017-01-24 | ||
| PCT/IB2018/050403 WO2018138634A1 (en) | 2017-01-24 | 2018-01-23 | Method for the treatment of thromboembolism |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110214015A true CN110214015A (zh) | 2019-09-06 |
Family
ID=61224209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880007480.0A Pending CN110214015A (zh) | 2017-01-24 | 2018-01-23 | 用于治疗血栓栓塞的方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20180206867A1 (ja) |
| EP (3) | EP3936140B1 (ja) |
| JP (2) | JP2020506907A (ja) |
| KR (1) | KR20190110095A (ja) |
| CN (1) | CN110214015A (ja) |
| AU (1) | AU2018212778A1 (ja) |
| CA (1) | CA3050858A1 (ja) |
| SG (1) | SG11201906431UA (ja) |
| TW (1) | TW201827074A (ja) |
| WO (1) | WO2018138634A1 (ja) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002359576A1 (en) | 2001-12-03 | 2003-06-17 | Ekos Corporation | Catheter with multiple ultrasound radiating members |
| US10182833B2 (en) | 2007-01-08 | 2019-01-22 | Ekos Corporation | Power parameters for ultrasonic catheter |
| PL2170181T3 (pl) | 2007-06-22 | 2014-08-29 | Ekos Corp | Sposób i aparat do leczenia wylewów wewnątrzczaszkowych |
| CN107708581B (zh) | 2015-06-10 | 2021-11-19 | Ekos公司 | 超声波导管 |
| JP2020103418A (ja) * | 2018-12-26 | 2020-07-09 | 株式会社三洋物産 | 遊技機 |
| US11717139B2 (en) | 2019-06-19 | 2023-08-08 | Bolt Medical, Inc. | Plasma creation via nonaqueous optical breakdown of laser pulse energy for breakup of vascular calcium |
| WO2020256898A1 (en) | 2019-06-19 | 2020-12-24 | Boston Scientific Scimed, Inc. | Balloon surface photoacoustic pressure wave generation to disrupt vascular lesions |
| US11660427B2 (en) | 2019-06-24 | 2023-05-30 | Boston Scientific Scimed, Inc. | Superheating system for inertial impulse generation to disrupt vascular lesions |
| US20200406009A1 (en) | 2019-06-26 | 2020-12-31 | Boston Scientific Scimed, Inc. | Focusing element for plasma system to disrupt vascular lesions |
| US10792054B1 (en) | 2019-07-11 | 2020-10-06 | Eduardo Lorenzo | Catheter for thromboembolic disease with mechanic waves, injection and ejection |
| US11583339B2 (en) | 2019-10-31 | 2023-02-21 | Bolt Medical, Inc. | Asymmetrical balloon for intravascular lithotripsy device and method |
| US12102384B2 (en) | 2019-11-13 | 2024-10-01 | Bolt Medical, Inc. | Dynamic intravascular lithotripsy device with movable energy guide |
| US11672599B2 (en) | 2020-03-09 | 2023-06-13 | Bolt Medical, Inc. | Acoustic performance monitoring system and method within intravascular lithotripsy device |
| US20210290286A1 (en) | 2020-03-18 | 2021-09-23 | Bolt Medical, Inc. | Optical analyzer assembly and method for intravascular lithotripsy device |
| US11707323B2 (en) | 2020-04-03 | 2023-07-25 | Bolt Medical, Inc. | Electrical analyzer assembly for intravascular lithotripsy device |
| JP2021186294A (ja) * | 2020-05-29 | 2021-12-13 | 株式会社三洋物産 | 遊技機 |
| US12016610B2 (en) | 2020-12-11 | 2024-06-25 | Bolt Medical, Inc. | Catheter system for valvuloplasty procedure |
| US11672585B2 (en) | 2021-01-12 | 2023-06-13 | Bolt Medical, Inc. | Balloon assembly for valvuloplasty catheter system |
| US11648057B2 (en) | 2021-05-10 | 2023-05-16 | Bolt Medical, Inc. | Optical analyzer assembly with safety shutdown system for intravascular lithotripsy device |
| US11806075B2 (en) | 2021-06-07 | 2023-11-07 | Bolt Medical, Inc. | Active alignment system and method for laser optical coupling |
| US11839391B2 (en) | 2021-12-14 | 2023-12-12 | Bolt Medical, Inc. | Optical emitter housing assembly for intravascular lithotripsy device |
| TWI848861B (zh) * | 2023-11-21 | 2024-07-11 | 財團法人金屬工業研究發展中心 | 超音波輔助血栓消融裝置 |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5399158A (en) * | 1990-05-31 | 1995-03-21 | The United States Of America As Represented By The Secretary Of The Army | Method of lysing thrombi |
| JPH07265417A (ja) * | 1994-04-01 | 1995-10-17 | Katsuro Tachibana | 薬物投与器具 |
| US5509896A (en) * | 1994-09-09 | 1996-04-23 | Coraje, Inc. | Enhancement of thrombolysis with external ultrasound |
| US5945432A (en) * | 1995-12-22 | 1999-08-31 | The University Of Vermont And State Agricultural College | Thrombolytic agents and thienopyridine derivatives in acute stroke |
| US20020138036A1 (en) * | 2001-03-21 | 2002-09-26 | Eilaz Babaev | Ultrasonic catheter drug delivery method and device |
| US20040122354A1 (en) * | 2002-09-05 | 2004-06-24 | Semba Charles P. | Infusion catheter having an integrated doppler transducer |
| US20070265560A1 (en) * | 2006-04-24 | 2007-11-15 | Ekos Corporation | Ultrasound Therapy System |
| US20080171965A1 (en) * | 2007-01-08 | 2008-07-17 | Ekos Corporation | Power parameters for ultrasonic catheter |
| CN101505785A (zh) * | 2006-08-29 | 2009-08-12 | 健泰科生物技术公司 | 替奈普酶用于治疗急性缺血性中风的用途 |
| CN103228224A (zh) * | 2010-08-27 | 2013-07-31 | Ekos公司 | 用于治疗颅内出血的方法和设备 |
| CN105025977A (zh) * | 2013-03-14 | 2015-11-04 | Ekos公司 | 用于将药物递送至靶部位的方法和设备 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5447509A (en) * | 1991-01-11 | 1995-09-05 | Baxter International Inc. | Ultrasound catheter system having modulated output with feedback control |
| AU2002359576A1 (en) | 2001-12-03 | 2003-06-17 | Ekos Corporation | Catheter with multiple ultrasound radiating members |
| WO2010075445A1 (en) * | 2008-12-23 | 2010-07-01 | Silk Road Medical, Inc. | Methods and systems for treatment of acute ischemic stroke |
| US20110082396A1 (en) * | 2009-10-06 | 2011-04-07 | Wallace Michael P | Ultrasound-enhanced stenosis therapy |
| US11458290B2 (en) * | 2011-05-11 | 2022-10-04 | Ekos Corporation | Ultrasound system |
-
2018
- 2018-01-23 SG SG11201906431UA patent/SG11201906431UA/en unknown
- 2018-01-23 US US15/878,269 patent/US20180206867A1/en active Pending
- 2018-01-23 WO PCT/IB2018/050403 patent/WO2018138634A1/en unknown
- 2018-01-23 EP EP21173294.6A patent/EP3936140B1/en active Active
- 2018-01-23 EP EP18705178.4A patent/EP3573635B1/en active Active
- 2018-01-23 EP EP23193805.1A patent/EP4272818A3/en active Pending
- 2018-01-23 CN CN201880007480.0A patent/CN110214015A/zh active Pending
- 2018-01-23 JP JP2019539808A patent/JP2020506907A/ja active Pending
- 2018-01-23 CA CA3050858A patent/CA3050858A1/en active Pending
- 2018-01-23 TW TW107102370A patent/TW201827074A/zh unknown
- 2018-01-23 KR KR1020197020966A patent/KR20190110095A/ko not_active IP Right Cessation
- 2018-01-23 AU AU2018212778A patent/AU2018212778A1/en active Pending
-
2023
- 2023-05-24 JP JP2023085321A patent/JP2023120202A/ja active Pending
Patent Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5399158A (en) * | 1990-05-31 | 1995-03-21 | The United States Of America As Represented By The Secretary Of The Army | Method of lysing thrombi |
| JPH07265417A (ja) * | 1994-04-01 | 1995-10-17 | Katsuro Tachibana | 薬物投与器具 |
| US5509896A (en) * | 1994-09-09 | 1996-04-23 | Coraje, Inc. | Enhancement of thrombolysis with external ultrasound |
| US5945432A (en) * | 1995-12-22 | 1999-08-31 | The University Of Vermont And State Agricultural College | Thrombolytic agents and thienopyridine derivatives in acute stroke |
| US20020138036A1 (en) * | 2001-03-21 | 2002-09-26 | Eilaz Babaev | Ultrasonic catheter drug delivery method and device |
| US20040122354A1 (en) * | 2002-09-05 | 2004-06-24 | Semba Charles P. | Infusion catheter having an integrated doppler transducer |
| US20070265560A1 (en) * | 2006-04-24 | 2007-11-15 | Ekos Corporation | Ultrasound Therapy System |
| CN101505785A (zh) * | 2006-08-29 | 2009-08-12 | 健泰科生物技术公司 | 替奈普酶用于治疗急性缺血性中风的用途 |
| US20080171965A1 (en) * | 2007-01-08 | 2008-07-17 | Ekos Corporation | Power parameters for ultrasonic catheter |
| CN103228224A (zh) * | 2010-08-27 | 2013-07-31 | Ekos公司 | 用于治疗颅内出血的方法和设备 |
| CN105361923A (zh) * | 2010-08-27 | 2016-03-02 | Ekos公司 | 用于治疗颅内出血的方法和设备 |
| CN105025977A (zh) * | 2013-03-14 | 2015-11-04 | Ekos公司 | 用于将药物递送至靶部位的方法和设备 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20180206867A1 (en) | 2018-07-26 |
| EP4272818A2 (en) | 2023-11-08 |
| JP2023120202A (ja) | 2023-08-29 |
| WO2018138634A1 (en) | 2018-08-02 |
| EP3936140A1 (en) | 2022-01-12 |
| SG11201906431UA (en) | 2019-08-27 |
| EP3573635B1 (en) | 2021-05-12 |
| CA3050858A1 (en) | 2018-08-02 |
| EP4272818A3 (en) | 2024-02-14 |
| TW201827074A (zh) | 2018-08-01 |
| EP3936140B1 (en) | 2023-08-30 |
| AU2018212778A1 (en) | 2019-07-11 |
| EP3573635A1 (en) | 2019-12-04 |
| JP2020506907A (ja) | 2020-03-05 |
| KR20190110095A (ko) | 2019-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110214015A (zh) | 用于治疗血栓栓塞的方法 | |
| US11925367B2 (en) | Power parameters for ultrasonic catheter | |
| US9192566B2 (en) | Treatment of vascular occlusions using ultrasonic energy and microbubbles | |
| Daffertshofer et al. | Ultrasound in the treatment of ischaemic stroke | |
| Tachibana | Enhancement of fibrinolysis with ultrasound energy | |
| US20190223895A1 (en) | Ultrasound pulse shaping | |
| Suchkova et al. | Effect of 40-kHz ultrasound on acute thrombotic ischemia in a rabbit femoral artery thrombosis model: enhancement of thrombolysis and improvement in capillary muscle perfusion | |
| Luo et al. | Transcutaneous ultrasound augments lysis of arterial thrombi in vivo | |
| US20160082243A1 (en) | Catheter system | |
| US11458290B2 (en) | Ultrasound system | |
| US20120271203A1 (en) | Power parameters for ultrasonic catheter | |
| WO2004022153A2 (en) | Infusion catheter having an integrated doppler transducer | |
| US20090187137A1 (en) | Ultrasound pulse shaping | |
| Porter et al. | Effectiveness of transcranial and transthoracic ultrasound and microbubbles in dissolving intravascular thrombi. | |
| US20120029397A1 (en) | Tumor treatment using ultrasound cavitation | |
| Rubiera et al. | Sonothrombolysis in the management of acute ischemic stroke | |
| Zhu et al. | Intra-clot microbubble-enhanced ultrasound accelerates catheter-directed thrombolysis for deep vein thrombosis: a clinical study | |
| Papadopoulos et al. | In vitro evaluation of focused ultrasound-enhanced TNK-tissue plasminogen activator-mediated thrombolysis | |
| Papadopoulos et al. | Microbubble-based sonothrombolysis using a planar rectangular ultrasonic transducer | |
| CN116058919B (zh) | 血栓消散导管及具有该导管的球囊导管组件 | |
| Abi-Jaoudeh et al. | Pulsed High–Intensity-focused US and Tissue Plasminogen Activator (TPA) Versus TPA Alone for Thrombolysis of Occluded Bypass Graft in Swine | |
| Feng et al. | Ultrasound Combined With Continuous Microbubble Injection to Enhance Catheter‐Directed Thrombolysis in Vitro and in Vivo | |
| US8364256B2 (en) | Method and apparatus of removal of intravascular blockages |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190906 |